Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a strong sell rating to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports.

Separately, Wall Street Zen downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.00.

Verrica Pharmaceuticals Trading Down 3.4%

VRCA opened at $7.15 on Monday. The company’s 50 day moving average is $5.98 and its 200-day moving average is $6.29. Verrica Pharmaceuticals has a 1-year low of $3.28 and a 1-year high of $9.82. The company has a current ratio of 2.59, a quick ratio of 2.45 and a debt-to-equity ratio of 0.03. The company has a market cap of $122.84 million, a P/E ratio of -4.53 and a beta of 1.54.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. The company had revenue of $5.02 million during the quarter, compared to analyst estimates of $4.51 million. Equities research analysts predict that Verrica Pharmaceuticals will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter worth approximately $122,000. Quadrature Capital Ltd bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at $99,000. Man Group plc bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at $94,000. Armistice Capital LLC increased its stake in shares of Verrica Pharmaceuticals by 75.1% in the 4th quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after acquiring an additional 479,732 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Verrica Pharmaceuticals in the 4th quarter valued at $276,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.